Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Nutra Pharma, a biotechnology company developing treatments for adrenomyeloneuropathy (AMN), HIV and multiple sclerosis (MS), has announced that sales of its over-the-counter (OTC) pain reliever, Cobroxin, totaled $583,955 for the fourth quarter ending December 31, 2009.
Subscribe to our email newsletter
Rik Deitsch, chairman and CEO of Nutra Pharma, said: “We were extremely pleased with our fourth quarter Cobroxin sales, especially given its initial limited retail availability. With the positive feedback we have received from Cobroxin consumers and retailers, we remain optimistic about the future growth of Cobroxin as we move into 2010.”
Cobroxin is clinically proven to treat moderate to severe (stage 2) chronic pain. The drug, which began selling in mid-October 2009, is currently available as an oral spray for treating lower back pain, migraines, neck aches, shoulder pain, cramps and neuralgia and as a topical gel for treating joint pain and pain associated with repetitive stress and arthritis.
Cobroxin is currently sold online and through retailers. It is distributed by XenaCare, a consumer products company licensed to market and distribute Cobroxin throughout the US.